WASHINGTON, June 16 /PRNewswire/ -- David Lawrence, chief financial officer of Acorda Therapeutics Inc., will testify Monday on behalf of the Biotechnology Industry Organization (BIO) at the House Government Reform Subcommittee on Regulatory Affairs field hearing regarding reform to Section 404 of the Sarbanes-Oxley Act of 2002.
